Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITPR3 | Q14573 | 8/20 | 1.00 |
| ▸ | ITPR2 | Q14571 | 4/20 | 0.94 |
| ▸ | ITPR1 | Q14643 | 4/20 | 0.94 |
| ▸ | INPP5A | Q14642 | 2/20 | 0.80 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.80 |
| ▸ | AKT1 | P31749 | 1/20 | 0.80 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atrinositol SCHEMBL134177 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL9022890 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL636077 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL355653 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL9489238 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL30474862 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL29370539 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL180074 | 1.00 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| Atrinositol SCHEMBL26683544 | 0.97 | ITPR3 (0.95) | ITPR3ITPR2ITPR1INPP5AINPPL1 | |
| SCHEMBL405897 | 0.97 | ITPR3 (1.00) | ITPR3ITPR2ITPR1INPP5AINPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | claimed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | claimed |
| US-20090175924-A1 | COATED STENT | BIONERIS AB (SE) | 2009-07-09 | — | — | US | claimed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | claimed |
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | LEVY ANDREW | 2009-02-26 | — | — | US | claimed |
| WO-2008153908-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF INTRAPLAQUE HEMORRHAGE | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2008-12-18 | — | — | WO | claimed |
| EP-1390045-B1 | THE USE OF A COMPOUND WITH A NEGATIVELY CHARGED DOMAIN OF PHOSPHOROUS-CONTAINING RADICALS FOR THE TREATMENT OF RESTENOSIS | BIONERIS AB (SE) | 2008-12-03 | — | — | EP | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| JP-2005537105-A | — | — | 2005-12-08 | — | — | JP | claimed |
| WO-1993016705-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1993-09-02 | — | — | WO | claimed |
| EP-0554861-A1 | The use of inositoltriphosphate for the treatment of renal diseases | PERSTORP AB (SE) | 1993-08-11 | — | — | EP | claimed |
| EP-0359260-B1 | THE USE OF INOSITOLTRISPHOSPHATE FOR THE PREPARING OF A MEDICAMENT AGAINST ABNORMAL LEVELS OF LIPOPROTEINS | PERSTORP AB (SE) | 1993-04-21 | — | — | EP | claimed |
| EP-0536269-A1 | THE USE OF INOSITOLTRISPHOSPHATE FOR THE PREPARING OF MEDICAMENTS | PERSTORP AB (SE) | 1993-04-14 | — | — | EP | claimed |
| EP-0359259-B1 | THE USE OF INOSITOLTRISPHOSPHATE FOR THE PREPARING OF A MEDICAMENT AGAINST TRANSPLANTATION DISORDERS | PERSTORP AB (SE) | 1992-08-19 | — | — | EP | claimed |
| US-5128332-A | Method of treating cardiovascular diseases using inositoltrisphosphate | PERSTORP AB (SE) | 1992-07-07 | — | — | US | claimed |
| WO-1992000079-A1 | THE USE OF INOSITOLTRISPHOSPHATE FOR THE PREPARING OF MEDICAMENTS | PERSTORP AB (SE) | 1992-01-09 | — | — | WO | claimed |
| US-5057507-A | Method of alleviating bone damage with inositoltriphosphate | PERSTORP AB (SE) | 1991-10-15 | — | — | US | claimed |
| EP-0359257-A2 | Use of inositol triphosphate in the preparation of a medicament against diabetes | PERSTORP AB (SE) | 1990-03-21 | — | — | EP | claimed |
| EP-0359260-A2 | The use of inositoltrisphosphate for the preparing of a medicament against abnormal levels of lipoproteins | PERSTORP AB (SE) | 1990-03-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | ITPR3 3281/4885ITPR2 3937/4885ITPR1 3918/4885 |
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | APOB, PPHLN1, SERPINC1 | ITPR3 2611/4885ITPR2 2734/4885ITPR1 2995/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | ITPR3 4534/4885ITPR2 4560/4885ITPR1 4377/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | ITPR3 4864/4885ITPR2 4875/4885ITPR1 4873/4885 |
| US-20090175924-A1 | COATED STENT | PHOSPHO1, SOST, PLCB3 | ITPR3 294/4885ITPR2 432/4885ITPR1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.